3Ievine A J, Momand J Fincav CA. The p53 tumor suppressor gene[ J]. Nature, 1991,351:453.
4Hiyushi H, Matasuno Y,Katu H,et al. Clinicopathological significance of nuclear accumulation of tumnr suppressor gene p53 product in primary lung cancer[ J]. Jpn J Cancer Res, 1992,83 : 101.
5Chen YW, Klimstra DS, Mongeau ME, et al Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells [ J ]. Cancer Res ,2007,15 ;67 (16) :7589 - 7596.
6Yamashita SI, Masuda Y,Yoshida N,et al. p53/AIPI Expression can be a Prognostic Marker in Non - small Cell Lung Cancer[J]. Clin Oncol ( R Coll Radiol) ,2007,10,54 : 199 - 207.
7Husgafvel- Pursiainen K, Boffetta P, Kannio A,et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer [ J ]. Cancer Res, 2000,60 ( 11 ) : 2906 - 2911.
8Grossi F, Loprevite M, Chiaramondia M, et al. Prognostic significance of K - ras, p53, bcl - 2, PCNA, CD34 in radically resected non - small cell lung cancers[J]. Eur J Cancer,2003,39(9) :1242 - 1250.
9Schiller JH, Adak S, Feins RH,et al. Lack of prognostic significance of p53 and K - ras mutations in primary resected non - small - cell lung cancer on E4592: a laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy[J]. J Clin Oncol,2001,19(2) :448-457.
10Bast RC,Klug TL,St John E,et al.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer[J].N Engl J Med,1983,309(15):883-887.
1Wang Y,Wang Y,Li J,et al. PAX8: a sensitive and spe- cific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy [J]. J Hematol Oncol, 2013,6: 60.
2Ordonez NG. Value of PAX 8 immunostaining in tumor diagnosis:a review and update [J]. Adv Anat Pathol,2012, 19(3) : 140-151.
3Xiang L, Kong B. PAX8 is a novel marker for differentiat- ing between various types of tumor,particularly ovarian epithelial carcinomas [J]. Oncol Lett, 2013,5 (3) : 735-738.
4Liliac L,Carcangiu ML,Canevari S,et aL The value of PAX8 and WT1 molecules in ovarian cancer diagnosis [J]. Rom J Morphol Embryo1,2013,54( 1 ) : 17-27.
5Laury AR,Perets R,Piao H,et al. A comprehensive analy- sis of PAX8 expression in human epithelial tumors [J]. Am J Surg Pathol, 2011,35(6) : 816-826.
6Zhao L; Guo M, Sneige N, et al. Value of PAX8 and WT1 Immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens [J]. Am J Clin Pathol,2012,137(2) :304-309.
7Tong GX,Devaraj K,Hamele-Bena D,et al. PaxS:a mark- er for carcinoma of Mtillerian origin in serous effusions [J]. Diagn Cytopathol, 2011,39 (8) : 567-574.
8Ordonez NG. Value of PAX8, PAX2, claudin-4, and h- caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas [J]. Mod Pathol, 2013,26(4) :553-562.
9Wiseman W,Michael CW,Roh MH. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identifi- cation of metastatic Mtillerian carcinoma in effusions [J]. Diagn Cytopathol, 2011,39 (9) : 651-656.
10Hu A,Li H,Zhang L,et al. Differentiating primary and extragenital metastatic mucinous ovarian tumours :an algo- rithm combining PAX8 with tumour size and laterality [J]. J Clin Pathol,2015,68(7) :522-528.
